SCHEMBL1622079

SCHEMBL1622079

Cc1cc(Cl)cc(-c2ccc(C(C)(C)C)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 4/20 0.47
RXRB P28702 4/20 0.47
TSHR P16473 1/20 0.46
AKR1C2 P52895 1/20 0.44
AKR1C1 Q04828 1/20 0.44
KIF11 P52732 4/20 0.44
CNR2 P34972 2/20 0.43
CNR1 P21554 2/20 0.43
GAA P10253 1/20 0.38
POLB P06746 1/20 0.37
RXRG P48443 1/20 0.37
XDH P47989 1/20 0.36
ADORA1 P30542 2/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14666772 0.88 CNR1 (0.51) RXRARXRBTSHRAKR1C2AKR1C1
SCHEMBL15110562 0.86 TSHR (0.56) RXRARXRBTSHRAKR1C2AKR1C1
SCHEMBL13589943 0.81 RXRA (0.42) RXRARXRBAKR1C2AKR1C1CNR2
SCHEMBL23446392 0.79 AKR1C2 (0.43) RXRARXRBTSHRAKR1C2AKR1C1
SCHEMBL16016368 0.78 ADORA1 (0.53) RXRARXRBPOLBADORA1NPC1
SCHEMBL15125620 0.77 RXRA (0.51) RXRARXRBTSHRAKR1C2AKR1C1
SCHEMBL1622290 0.77 RXRA (0.47) RXRARXRBTSHRAKR1C2AKR1C1
SCHEMBL5049965 0.77 KIF11 (0.56) TSHRAKR1C2AKR1C1KIF11CNR1
SCHEMBL13538918 0.76 TSHR (0.47) RXRARXRBTSHRCNR2CNR1
SCHEMBL23319641 0.76 KIF11 (0.61) RXRARXRBTSHRAKR1C2AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791104-B2 1,4-benzodiazepine-2,5-diones with therapeutic properties THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-07-29 US disclosed
US-8716281-B2 Pyrimidine compounds that inhibit anaplastic lymphoma kinase AMGEN INC. (US) 2014-05-06 US disclosed
US-20130261110-A1 NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2013-10-03 US disclosed
US-20130158019-A1 PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE AMGEN INC. (US) 2013-06-20 US disclosed
US-20120088757-A1 NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130261110-A1 NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES BAD, GABRA5, GABRB1 RXRA 263/4885RXRB 135/4885TSHR 980/4885
US-20130158019-A1 PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE DCK, DTYMK, TYMS RXRA 2333/4885RXRB 2183/4885TSHR 4246/4885
US-20120088757-A1 NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES BAD, GABRA5, GABRB1 RXRA 263/4885RXRB 135/4885TSHR 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.